Publications by authors named "K Schewe"
Article Synopsis
- Between 2013 and 2016, the effectiveness of the A/H1N1pdm09 component in the live attenuated influenza vaccine (LAIV) was lower than expected, prompting a need for better predictive models.
- Researchers optimized the vaccine dose in ferret models and used clinically relevant outcomes, focusing on virus shedding and fever rather than just serum immunogenicity.
- The study found that LAIV formulations with higher vaccine efficacy showed significantly better protection against H1N1 challenges, highlighting the importance of dosing and endpoint selection in evaluating vaccine effectiveness.
Introduction: Direct-acting antivirals (DAAs) are key to eliminating hepatitis C virus (HCV). In men who have sex with men (MSM) with HIV co-infection, recently acquired HCV infection is common. Sexual practices and reinfection rates may hamper micro-elimination despite high treatment rates.
View Article and Find Full Text PDFObjectives: To identify sexual/sex-associated risk factors for hepatitis C transmission among men who have sex with men (MSM) and visualise behavioural trajectories from 2019 to 2021.
Methods: We linked a behavioural survey to a hepatitis C cohort study (NoCo), established in 2019 across six German HIV/hepatitis C virus (HCV) treatment centres, and performed a case-control analysis. Cases were MSM with recent HCV infection, and controls were matched for HIV status (model 1) or proportions of sexual partners with HIV (model 2).
[Evaluating the introduction of HIV pre-exposure prophylaxis as a benefit of statutory health insurance (EvE-PrEP) : Highly effective protection against HIV without an increase in sexually transmitted infections].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
September 2023
Background: We investigated the impact of HIV pre-exposure prophylaxis (PrEP) as a new service of the statutory health insurance (SHI) on the incidence of HIV and other sexually transmitted infections (STIs) in Germany. In addition, PrEP needs and access barriers were analyzed.
Methods: The following data were evaluated as part of the evaluation project: HIV and syphilis notification data and extended surveillance by the Robert Koch Institute (RKI), pharmacy prescription data, SHI routine data, PrEP use in HIV-specialty care centers, Checkpoint, the BRAHMS and PrApp studies, as well as a community board.